An Open Label Pilot Study of Atomoxetine Hydrochloride in Adolescents with Attentioin-Deficit/Hyperactivity Disorder and Comorbid Cannabis Abuse

Eli Lilly Nederland0 sitesMarch 6, 2008

ConditionsAttention Deficit Hyperactivity Disorder MedDRA version: 9.1Level: LLTClassification code 10003736Term: Attention deficit/hyperactivity disorder

DrugsStrattera

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Attention Deficit Hyperactivity Disorder
Sponsor: Eli Lilly Nederland
Status: Active, not recruiting
Last Updated: 14 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

March 6, 2008

End Date

TBD

Last Updated

14 years ago

Study Type

Interventional clinical trial of medicinal product

Sex

All

Investigators

Sponsor

Eli Lilly Nederland

Eligibility Criteria

Inclusion Criteria

•Patients are eligible to be included in the study only if they meet all of the following criteria:
•(1\) Patients must be male and female patients who are at least 13 years of age and not more than 17 years of age when the informed consent document is obtained.
•(2\) Patients must have a diagnosis of ADHD based on the Diagnostic and Statistical Manual of Mental Disorders\-Fourth Edition\-Text Revision© (DSM\-IV\-TR©) criteria for ADHD. For the purpose of this study the diagnosis of ADHD will be confirmed during Visit 1 by administering the Kiddie Schedule for Affective Disorders and Schizophrenia for School Aged Children\-Present and Lifetime Version (K\-SADS\-PL).
•(3\) At Visit 1 and 2 patients must score at least 1\.5 standard deviations above the age norm for their diagnostic subtype using published norms for the ADHD Rating Scale\-IV\-Parent Version (See Protocol Attachment LYEL.5\). In addition, they must have a CGI\-ADHD\-S score ?4 at both Visit 1 and Visit 2
•(4\) Patients must meet DSM\-IV\-TR© criteria for cannabis abuse or dependence and use cannabis at minimum of 5 joints per week during the last month before enrollment. Current abstinence is allowed the week before enrollment.
•(5\) Patients must be of normal intelligence as assessed by the investigator (that is, without a general impairment of intelligence and likely, in the investigator’s judgment, to achieve a score of ?80 on an IQ test).
•(6\) Patients and parents (legal representative) have been judged by the investigator to be reliable to keep appointments for clinic visits, all tests and examinations required by the protocol.
•(7\) This Inclusion criterion applies to all females.
•Test negative for pregnancy at the time of enrollment based on a urine pregnancy test and agree to use a reliable method of birth control if they are sexually active (for example, use of oral contraceptives or Norplant®; a reliable barrier method of birth control \[diaphragms with contraceptive jelly; cervical caps with contraceptive jelly; condoms with contraceptive foam; intrauterine devices]; partner with vasectomy; or abstinence) during the study and for 1 week following the last dose of study drug].
•(8\) Patients must be able to swallow capsules (study drug).

Exclusion Criteria

•(9\) Patients who weigh less than 20 kg at Visit 1\.
•(10\) Patients with a history of Bipolar I or II disorder, schizophrenia, another psychotic disorder.
•(11\) Patients who have a significant medical condition such as heart disease, prolonged QT interval, hypertension, liver or renal failure, pulmonary disease, or seizure disorder identified by history, physical examination, or laboratory tests. Patients who have taken (or are currently taking) anticonvulsants for seizure control.
•(12\) Patients determined by the investigator to be at serious suicidal risk. This evaluation must include the items a, b, c, d and e of K\-SADS\-PL’s depression module, and there can not be a score of 3 in any of these items.
•(13\) Patients with a history of alcohol or drug (other than cannabis) abuse within the past 3 months (excessive or compulsive use as judged by the investigator), or who are currently using alcohol in a manner which the investigator considers indicative of abuse or any drugs of abuse (other than cannabis), or any prescribed or over\-the\-counter medication in a manner which the investigtor considers indicative of abuse.
•(14\) Patients with a history of severe allergies to more than 1 class of medications or multiple adverse drug reactions.
•(15\) Patients who, prior to this study, did not respond to or did not tolerate atomoxetine.
•(16\) Patients with cardiovascular disease or other conditions that could be aggravated by an increased heart rate or increased blood pressure.
•(17\) Patients who have a medical condition that would increase sympathetic nervous system activity markedly (for example, catecholamine\-secreting neural tumour), or who are taking a medication on a daily basis, (for example, albuterol, inhalation aerosols, pseudoephedrine) that has sympathomimetic activity are excluded.
•(18\) Patients who in the investigator’s judgment are likely to need psychotropic medications apart from the drug under study, including health\-food supplements that in the investigator’s opinion have central nervous system activity (for example, St.John’s Wort, melatonin).